Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600135042) titled 'Multicenter Prospective Clinical Study on G-CSF + Venetoclax + Cladribine + Cytarabine for Relapsed/Refractory and Newly Diagnosed Non-Response AML' on Oct. 23.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: First Affiliated Hospital of Harbin Medical University
Condition:
Acute Myeloid Leukemia, AML
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-11-01
Target Sample Size: Acute Myeloid Leukemia:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=343512
Disclaimer: Curated by HT Syndication....